.png)
Amgen pads Imdelltra's case in tough-to-treat lung cancer subtype with phase 3 survival win
The drug won an accelerated approval last year in extensive-stage small cell lung cancer based on a large phase 2 study that proved benefits in overall response rate and duration of response.
The drug won an accelerated approval last year in extensive-stage small cell lung cancer based on a large phase 2 study that proved benefits in overall response rate and duration of response.
